Research Topics
| D L DunnerSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depressionDavid L Dunner
Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA
J Clin Psychiatry 67:688-95. 2006..We report on the characteristics and outcomes of a large cohort of patients with a level of treatment resistance that is very substantial and who were treated for 2 years with standard care...
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trialsDavid L Dunner
Center for Anxiety and Depression, University of Washington, Seattle, Washington 98105 6099, USA
Clin Ther 27:1901-11. 2005..The aims of this work were to assess the efficacy and tolerability of controlled-release paroxetine (paroxetine CR) in the treatment of outpatients with severe major depressive disorder (MDD)...
Safety and tolerability of emerging pharmacological treatments for bipolar disorderDavid L Dunner
Center for Anxiety and Depression, and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98105, USA
Bipolar Disord 7:307-25. 2005..As the armamentarium for treating BPD increases, it allows for the possibility of choosing drugs on the basis of their tolerability as well as their efficacy, rather than on efficacy alone...
Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
J Affect Disord 87:115-9. 2005..This study investigated the rate of hypomania, mania, and hypomanic-like symptoms observed during treatment with duloxetine in patients with major depression...
Atypical antipsychotics: efficacy across bipolar disorder subpopulationsDavid L Dunner
Center for Anxiety and Depression, University of Washington, Seattle, WA 98105 6099, USA
J Clin Psychiatry 66:20-7. 2005..In addition, they have shown effectiveness and tolerability in small-scale and open-label trials and case studies with pediatric and geriatric bipolar patients...
Correlates of suicidal behavior and lithium treatment in bipolar disorderDavid L Dunner
Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105 6099, USA
J Clin Psychiatry 65:5-10. 2004..Research does tend to agree that lithium is efficacious in decreasing suicidal behavior in patients with affective disorders...
Dysthymia and double depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Medical School, Washington 98105, USA
Int Rev Psychiatry 17:3-8. 2005..This paper renews the diagnostic status of dysthymic disorder, treatment studies, and makes suggestions for the classification of chronic forms of depression for DSM-V...
Treatment considerations for depression in the elderlyDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA
CNS Spectr 8:14-9. 2003..This article discusses pharmacotherapeutic and psychotherapeutic approaches to the treatment of depression in the elderly population...
Drug interactions of lithium and other antimanic/mood-stabilizing medicationsDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, and the Center for Anxiety and Depression, Seattle 98105, USA
J Clin Psychiatry 64:38-43. 2003..Successful management of medications for the patient with bipolar disorder is a challenge, but increased effort and vigilance by clinicians mean a reduced risk of hospitalization and fewer office visits for patients...
Duration of periods of euthymia in patients with dysthymic disorderD L Dunner
Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington, Seattle, USA
Am J Psychiatry 156:1992-3. 1999..The purpose of this study was to assess the duration of periods of euthymia in patients with dysthymia...
Optimizing lithium treatmentD L Dunner
Department of Psychiatry and Behavioral Sciences and the Center for Anxiety and Depression, University of Washington, Seattle, USA
J Clin Psychiatry 61:76-81. 2000..Since side effects can affect compliance, recognition and treatment of early and late-appearing side effects are important aspects of lithium pharmacotherapy...
Acute and maintenance treatment of chronic depressionD L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105 6099, USA
J Clin Psychiatry 62:10-6. 2001..Newer treatments, such as the combination of psychotherapy and pharmacotherapy, may prove to be of greatest benefit for individuals with chronic mood disorders...
Management of anxiety disorders: the added challenge of comorbidityD L Dunner
Department of Psychiatry and Behavioral Sciences and Center for Anxiety and Depression, University of Washington, 4225 Roosevelt Way NE, Suite 306 C, Seattle, Washington 98105, USA
Depress Anxiety 13:57-71. 2001..The impact of co-existing multiple anxiety disorders, depression, or a history of substance abuse will be discussed with a view to choosing the appropriate management strategy. Treatment options will be reviewed...
Six-year perspectives on the safety and tolerability of nefazodoneDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105-6099, USA
J Clin Psychiatry 63:32-41. 2002
The effect of anxiety disorder comorbidity on treatment resistant bipolar disordersJohn H Lee
Department of Biology, University of Washington, Seattle, Washington 98040, USA
Depress Anxiety 25:91-7. 2008..Anxiety disorders negatively impact the course of bipolar disorders. The high prevalence and risk rate of comorbid anxiety disorders in bipolar patients highlight the need for greater clinical attention to this population...
Differential subtyping of depressionT Yang
Department of Psychiatry and Behavioral Science, Center for Anxiety and Depression, University of Washington, 4225 Roosevelt Way NE, Suite 306C, Seattle, WA 98105-6099, USA
Depress Anxiety 13:11-7. 2001..However, in the course of reviewing the literature on this topic, very few studies have separated patients into these distinct depressive subtypes. Further studies are needed to indicate if these subtypes can be meaningfully separated...
Antidepressant-induced hypomania in treatment-resistant depressionCynthia D Bader
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
J Psychiatr Pract 13:233-7. 2007..However, the patients described in the literature have not had treatment-resistant depression...
Interactive case conference. First episode: depression and panic disorderDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
CNS Spectr 10:696-7. 2005
Clinical consequences of under-recognized bipolar spectrum disorderDavid L Dunner
Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington School of Medicine, Seattle, WA 98105, USA
Bipolar Disord 5:456-63. 2003..Depressive episodes are common in patients who experience BSDs, and increasingly treatment approaches designed specifically for bipolar depression are being studied...
Bipolar disorder not otherwise specified in relation to the bipolar spectrumCynthia D Bader
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
Bipolar Disord 9:860-7. 2007..Our hypothesis was that patients with BPD NOS would be more similar to other bipolar patients than major depressive disorder (MDD) patients in terms of age of onset, history of suicidal behavior and family history of BPD...
Duloxetine in treatment of anxiety symptoms associated with depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
Depress Anxiety 18:53-61. 2003..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies...
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depressionRachel Manber
Department of Psychiatry and Behavioral Sciences, Stanford University, CA 94305, USA
Sleep 26:130-6. 2003..The purpose of the study was to compare the effects of psychotherapy, nefazodone, and their combination on subjective measures of sleep in patients with chronic forms of major depression...
A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depressionDavid H Avery
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Harborview Medical Center, Seattle, 98104 2499, USA
Biol Psychiatry 59:187-94. 2006..Repetitive transcranial magnetic stimulation (TMS) as a treatment for depression has shown statistically significant effects, but the clinical significance of these effects has been questioned...
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorderDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, USA
Depress Anxiety 25:E1-8. 2008..The adverse events causing discontinuation during the extension phase were generally not unique to the extension phase. Few patients experienced significant weight gain...
Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled studyDavid H Avery
Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, Seattle, Washington 98104 2499, USA
J Nerv Ment Dis 195:378-81. 2007..Compared with sham, TMS was associated with a significant (p < 0.05) reduction in the SAFTEE pain item during the study. The reduction in pain could not be explained by the antidepressant effects...
Lithium and valproic acid treatment effects on brain chemistry in bipolar disorderSeth D Friedman
Department of Radiology, University of Washington, Seattle, Washington, USA
Biol Psychiatry 56:340-8. 2004..This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals...
A review of antidepressant-induced hypomania in major depression: suggestions for DSM-VBenjamin J D H Chun
Department of Psychiatry and Behavioral Science, Center for Anxiety and Depression, University of Washington, Seattle, WA 98105, USA
Bipolar Disord 6:32-42. 2004..Depressed patients who experience antidepressant-associated hypomania are truly bipolar...
Interactive case conference. Double depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington, Seattle, USA
CNS Spectr 10:174. 2005
Treatment-resistant bipolar disorder: a comparison of rapid cyclers and nonrapid cyclersDong Vo
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98015, USA
CNS Spectr 8:948-52. 2003..The study of treatment resistance among nonrapid-cycling bipolar patients merits further research...
Brain metabolic alterations in medication-free patients with bipolar disorderStephen R Dager
Department of Radiology, University of Washington, Seattle 98105, USA
Arch Gen Psychiatry 61:450-8. 2004..Bipolar disorder (BD) has substantial morbidity and incompletely understood neurobiological underpinnings...
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combinationRobert M A Hirschfeld
Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas 77555 0188, USA
Biol Psychiatry 51:123-33. 2002..This study compared efficacy of nefazodone, psychotherapy, and their combination in improving psychosocial functioning in chronically depressed outpatients...
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot studyDavid L Dunner
Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
J Clin Psychiatry 68:1071-7. 2007..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...
Bipolar depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
CNS Spectr 10:528. 2005
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depressionSona Dimidjian
Department of Psychology, University of Washington, USA
J Consult Clin Psychol 74:658-70. 2006..The implications of these findings for the evaluation of current treatment guidelines and dissemination are discussed...
Dysthymic disorder: treatment with citalopramDavid L Dunner
Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA
Depress Anxiety 15:18-22. 2002..Various criteria for response and remission were employed. These findings are intended to give guidelines for a subsequent treatment study of dysthymic patients with citalopram using a double-blind placebo-controlled strategy...
Interactive case conference: depression, dementia, or pseudodementia?David L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
CNS Spectr 10:862. 2005
Anxiety and depression in the elderly: implications for diagnosis and treatmentDavid L Dunner
Department of Psychiatry, University of Washington, Seattle, Washington, USA
CNS Spectr 8:5. 2003
Interactive case conference: Depression in the elderlyDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
CNS Spectr 10:354. 2005
Interactive case conference. First onset of schizophreniaDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
CNS Spectr 11:19. 2006
Rapid cycling bipolar disorder--diagnostic conceptsMichael Bauer
Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany
Bipolar Disord 10:153-62. 2008..This paper reviews the literature to examine the DSM-IV diagnostic criteria for rapid cycling in bipolar disorder...
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depressionKeith S Dobson
Department of Psychology, University of Calgary, Calgary, Alberta, Canada
J Consult Clin Psychol 76:468-77. 2008..These findings suggest that behavioral activation may be nearly as enduring as cognitive therapy and that both psychotherapies are less expensive and longer lasting alternatives to medication in the treatment of depression...
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyDavid Michelson
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
J Clin Psychiatry 68:582-7. 2007..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
A comparison of initial duloxetine dosing strategies in patients with major depressive disorderVirgil G Whitmyer
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
J Clin Psychiatry 68:1921-30. 2007..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
J Clin Psychiatry 68:1014-23. 2007..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller
Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
J Clin Psychiatry 68:1246-56. 2007..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller
Brown University, Providence, Rhode Island 02906, USA
Biol Psychiatry 62:1371-9. 2007..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
Preventing recurrent depression: long-term treatment for major depressive disorderPierre Blier
Department of Psychiatry, Institute of Mental Health Research, University of Ottawa, Canada
J Clin Psychiatry 68:e06. 2007..Maintenance therapy considerations for clinicians include assessing treatment guidelines, addressing nonadherent patients, and measuring medication treatment response...
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger
Lilly Research Laboratories, Indianapolis, IN 46285, USA
J Affect Disord 73:155-61. 2003..CONCLUSIONS: These results indicate that olanzapine was effective in reducing symptoms of mania and well tolerated in patients with bipolar I disorder with a rapid-cycling course...
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
J Clin Psychiatry 63:493-500. 2002..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances...
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg
Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
Biol Psychiatry 54:806-17. 2003..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD...
Efficacy of controlled-release paroxetine in the treatment of late-life depressionMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
J Clin Psychiatry 64:1065-74. 2003..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition...
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment...
Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depressionDaniel N Klein
Department of Psychology, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
J Consult Clin Psychol 72:681-8. 2004..The 2 conditions also differed significantly on change in depressive symptoms over time. These findings support the use of CBASP as a maintenance treatment for chronic forms of MDD...
The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medicationAlan J Gelenberg
University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
J Clin Psychiatry 65:1114-9. 2004..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 30:405-16. 2005..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings...
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood traumaCharles B Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322
Proc Natl Acad Sci U S A 100:14293-6. 2003..Our results suggest that psychotherapy may be an essential element in the treatment of patients with chronic forms of major depression and a history of childhood trauma...
Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10021, USA
Psychopharmacol Bull 37:73-87. 2003..COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters...
Regional cerebral cortical thinning in bipolar disorderIn Kyoon Lyoo
McLean Hospital Brain Imaging Center, Harvarrd Medical School, Boston, MA, USA
Bipolar Disord 8:65-74. 2006..This study was conducted to explore differences in cortical thickness between subjects with bipolar disorder and healthy comparison subjects using cortical surface-based analysis...
Basal ganglia shape alterations in bipolar disorderJaeuk Hwang
Department of Psychiatry, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, South Korea
Am J Psychiatry 163:276-85. 2006..The findings more generally demonstrate the sensitivity of the SPHARM analytic technique for detecting subtle anatomical shape differences in small brain regions in the absence of volume differences...
Frontal lobe gray matter density decreases in bipolar I disorderIn Kyoon Lyoo
Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478, USA
Biol Psychiatry 55:648-51. 2004..Decreased gray matter density in the right inferior frontal gyrus, which processes nonverbal and intrinsic functions, supports nondominant hemisphere dysfunction as a component of bipolar disorder...
The occurrence of cavum septi pellucidi enlargement is increased in bipolar disorder patientsMinue J Kim
McLean Hospital Brain Imaging Center, Harvard Medical School, Boston, MA, USA
Bipolar Disord 9:274-80. 2007..This study was conducted to evaluate the prevalence of cavum septi pellucidi (CSP) enlargement in patients with bipolar disorder (BD) and healthy comparison subjects...
Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force ReportS Nassir Ghaemi
Bipolar Disorder Research Program, Department of Psychiatry, Emory University, Atlanta, GA 30322, USA
Bipolar Disord 10:117-28. 2008....
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorderRichard C Shelton
Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn, USA
J Clin Psychiatry 67:1674-81. 2006..The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in outpatients with major depressive disorder...
